



Indirect ELISA for Detection of Fascioliasis IgG Antibodies in Human Sera

Journal of Health Disparities Research and Practice

Volume 9
Issue 5 Special Issue - NIDDK STEP UP

Article 95

© Center for Health Disparities Research, School of Public Health, University of Nevada, Las Vegas

2016

Indirect ELISA for Detection of Fascioliasis IgG Antibodies in Human Sera

Ernesto R. Ramos Maldonado

Ana M. Espino, PhD, University of Puerto Rico, Medical Sciences Campus

Follow this and additional works at: <https://digitalscholarship.unlv.edu/jhdrp>



Part of the Bilingual, Multilingual, and Multicultural Education Commons, Community College Leadership Commons, Higher Education Commons, Immune System Diseases Commons, Public Health Commons, Translational Medical Research Commons, and the Virus Diseases Commons

Recommended Citation

Ramos Maldonado, Ernesto R. and Espino, PhD, Ana M. (2016) "Indirect ELISA for Detection of Fascioliasis IgG Antibodies in Human Sera," *Journal of Health Disparities Research and Practice*: Vol. 9: Iss. 5, Article 95.

Available at: <https://digitalscholarship.unlv.edu/jhdrp/vol9/iss5/95>

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in Journal of Health Disparities Research and Practice by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

Indirect ELISA for Detection of Fascioliasis IgG Antibodies in Human Sera

Abstract

Currently, coprological examination based on egg detection in stool samples is used as the most ideal standard for the diagnosis of human fascioliasis. However, this method has been proven not to be adequate when being employed in the acute phase of the disease, and presents a poor sensitivity during the chronic phase. Serodiagnosis has become an excellent alternative to coprological examination in efforts to combat the effects of fascioliasis on human and animal health. Human fascioliasis is usually recognized as an infection of the bile ducts and liver caused by *Fasciola hepatica*, known to affect over 2 million humans.

In this research, Indirect Enzyme-linked Immunosorbent Assay (ELISA) was performed to discern between positive and negative IgG antibody titers in sera in collaboration with a lab in Peru. A batch of approximately 325 samples of human sera of endemic *Fasciola hepatica* from regions in Peru was gathered and sent to the laboratory in order to be examined with the method explained in the following paragraph.

In the search for a test for the diagnosis of fascioliasis on humans, indirect ELISA started to be employed in order to determine positive and negative values. In the indirect ELISA test, the sample antibody is sandwiched between the antigen coated on the plate and an enzyme-labeled, anti-species globulin conjugate. The addition of an enzyme substrate-chromogen reagent causes color to develop. This color is directly proportional to the amount of bound sample antibody. The more antibody present in the sample, the stronger the color development in the test wells. Positive samples presented a very strong optical density value, while negative samples were clear or low optical density value, measured with the aid of a spectrophotometer.

Keywords

Antigen; *Fasciola hepatica*; Antibody; Indirect ELISA



Journal of Health Disparities Research and Practice
Volume 9, Special Edition 1, Summer 2016, pp. 134
© 2011 Center for Health Disparities Research
School of Community Health Sciences
University of Nevada, Las Vegas

Indirect ELISA for Detection of Fascioliasis IgG Antibodies in Human Sera

Ernesto Raúl Ramos Maldonado

Ana M. Espino, PhD, University of Puerto Rico, Medical Sciences Campus

Coordinating Center: University of Nevada Las Vegas

ABSTRACT

Currently, coprological examination based on egg detection in stool samples is used as the most ideal standard for the diagnosis of human fascioliasis. However, this method has been proven not to be adequate when being employed in the acute phase of the disease, and presents a poor sensitivity during the chronic phase. Serodiagnosis has become an excellent alternative to coprological examination in efforts to combat the effects of fascioliasis on human and animal health. Human fascioliasis is usually recognized as an infection of the bile ducts and liver caused by *Fasciola hepatica*, known to affect over 2 million humans.

In this research, Indirect Enzyme-linked Immunosorbent Assay (ELISA) was performed to discern between positive and negative IgG antibody titers in sera in collaboration with a lab in Peru. A batch of approximately 325 samples of human sera of endemic *Fasciola hepatica* from regions in Peru was gathered and sent to the laboratory in order to be examined with the method explained in the following paragraph.

In the search for a test for the diagnosis of fascioliasis on humans, indirect ELISA started to be employed in order to determine positive and negative values. In the indirect ELISA test, the sample antibody is sandwiched between the antigen coated on the plate and an enzyme-labeled, anti-species globulin conjugate. The addition of an enzyme substrate-chromogen reagent causes color to develop. This color is directly proportional to the amount of bound sample antibody. The more antibody present in the sample, the stronger the color development in the test wells. Positive samples presented a very strong optical density value, while negative samples were clear or low optical density value, measured with the aid of a spectrophotometer.

Key words: Antigen, *Fasciola hepatica*, Antibody, Indirect ELISA

ACKNOWLEDGEMENTS

The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, Grant number: 1R25DK098067-01.